Duaa Kanan, Internal Medicine Resident Physician at University of Illinois College of Medicine Peoria, shared a post on LinkedIn:
“Last week, I presented the Hematology/ Oncology Grand Rounds Conference at the Department of Medicine. In this talk, I wanted to highlight new and exciting advances in the field of cancer genetics and precision oncology. We covered several clinical trials and their implications on patient care including the recent ALASCCA trial (published in the New England Journal of Medicine in Sep 2025).
Key point: It’s important to test for the PI3KCA mutation in select patients with colorectal cancer. Thank you to everyone who attended and contributed to a great discussion!”
You Can Also Read: ALASCCA Trial Results: Low-Dose Aspirin in PI3K-Altered CRC
